Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years

Medtronic (MDT) raised its dividend for 49 straight years while delivering $36 billion in revenue, its strongest top-line growth in 10 years.

Trading at 14x forward earnings with a beta of 0.597, MDT offers defensive value as non-discretionary procedures insulate it from market downturns.

A $185 million tariff headwind and 230-basis-point margin compression are near-term risks, but demographics and deep switching costs anchor the 20-year thesis.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Medtronic didn't make the cut. Grab the names FREE today .

For an investor in their 50s or 60s who is finished chasing trends, Medtronic ( NYSE:MDT ) is a stock worth owning for decades because it pairs inelastic demand for medical devices with a 49th consecutive year of dividend increases. A $2,500 stake at the current $80.33 share price buys roughly 31 shares of a business engineered to keep paying you while the rest of the market cycles through manias.

Medtronic is a diversified medical device juggernaut organized into four portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. That breadth matters because no single product cycle can sink the company. In fiscal 2026, revenue reached $36.36 billion, up 8.43% year over year, which CEO Geoff Martha called the "strongest annual top-line growth Medtronic has delivered in 10 years." Cardiovascular alone produced $3.80 billion in Q4, with Cardiac Ablation Solutions growing 78% globally and capturing 8 additional points of U.S. market share. Pacemakers, spinal implants, insulin pumps and surgical navigation systems train surgeons on Medtronic's proprietary ecosystems, creating switching costs that compound over decades alongside an aging global population that will keep filling cath labs and operating rooms.

The forever case rests heavily on cash returned to shareholders. The board declared a $0.72 quarterly dividend on June 3, 2026, implying $2.88 annually and a yield of roughly 3.52%. That payout is funded by $5.43 billion in free cash flow and $7.33 billion in operating cash flow, with another $1.035 billion spent on buybacks in fiscal 2026. The quarterly dividend has climbed from roughly $0.04 in 1999 to $0.71 in early 2026, with the latest bump making it 49 straight years of increases. That is dividend aristocrat territory, and it is exactly the kind of compounding a retirement portfolio is built around.

Procedure volumes for cardiac ablation, pacemakers, spinal fusion and diabetes management are largely non-discretionary. People do not postpone life-saving devices because the S&P 500 is in a drawdown. That defensiveness shows up in a beta of 0.597 and in four consecutive quarterly EPS beats. Management guided fiscal 2027 to organic revenue growth of 6.75% to 7.25% and non-GAAP EPS of $5.90 to $6.00. Shares trade at a forward multiple of roughly 14x, an attractive entry for a business this defensive.